c5l2 (or gpr77) is a high-affinity receptor for the complement fragment c5a and its desarginated product, c5a-desarg. unlike the classical c5a receptor cD88, c5l2 does not couple to intracellular g-protein-signaling pathways but is thought to function as a decoy receptor. the authors show that stimulation of c5l2 with c5a and c5a-desarg induces redistribution of green fluorescent protein-labeled β-arrestin2 to cytoplasmic vesicles. c3a and c3a-desarg were inactive in the β-arrestin translocation assay. Direct interaction of ligand-stimulated c5l2 with β-arrestin was confirmed using a novel β-galactosidase fragment complementation assay. in this assay, c5l2 was labeled with a mutationally altered peptide fragment of β-galactosidase, whereas β-arrestin2 was labeled with a corresponding deletion mutant of the enzyme. stable transfection of the modified c5l2 and subsequent stimulation with c5a or c5a-desarg restored β-galactosidase activity in a dose-dependent manner. the subnanomolar potency of β-arrestin coupling in the β-galactosidase fragment complementation assay is in agreement with the affinity of the receptor-ligand interaction. c5l2 is the first example of a 7-transmembrane decoy receptor that couples to β-arrestin in a ligand-dependent manner. this observation supports the notion that g-protein-signaling and β-arrestin coupling can be 2 separate activities of 7-transmembrane receptors. furthermore, the β-arrestin assays described in this article provide methods of screening for selective c5l2 modulators. (Journal of Biomolecular
INTRODUCTION
S even transmembrane receptors (7tms) constitute the largest family of proteins encoded by the human genome. 1 7tms are the receptors of a wide repertoire of endogenous and exogenous chemical messengers, including hormones, neurotransmitters, and chemoattractants. Due to their regulatory role in key physiological processes, 7tms represent a main focus area of pharmacological research. multiple diseases have been linked to mutations or polymorphisms in 7tms, 2 and they are the targets of many therapeutic agents. it has been estimated that 25% of prescription drugs worldwide exert their therapeutic effect through 7tms, making these receptors the most successful single drug target class at present. 3 according to the classical paradigm, 7tms signal by means of activation of heterotrimeric guanine nucleotidebinding proteins (g-proteins). these g-proteins regulate the activity of intracellular enzymes involved in the production and degradation of second messengers, such as cyclic amp (camp) and inositol phosphates. agonist activation also results in phosphorylation of the receptor by g-protein-coupled receptor kinases (grKs), 4 thereby creating a high-affinity binding site for the cytoplasmic protein β-arrestin. 5 β-arrestin prevents further g-protein coupling and targets the receptor to clathrin-coated pits for endocytosis. 6 once internalized, the receptor is dephosphorylated, and the ligand dissociates from the receptor due to the acidic interior of the endosomes. the internalized receptor is then either recycled to the plasma membrane or directed to lysosomes for degradation. 7 β-arrestin not only plays a key role in the attenuation of g-protein signaling but can also couple 7tms to signaling pathways using members of the src and mitogen-activated protein kinase (mapK) families, such as extracellular signal-regulated kinases 1 and 2 (erK1/2). 8 studies with mutated receptors and ligands and with β-arrestin knockout mice indicate that g-protein-dependent and β-arrestin-mediated signaling pathways can be separated. 9 for instance, a mutationally altered angiotensin peptide, denoted sii angiotensin, is unable to induce gαq-proteinmediated mobilization of second messengers, but it still activates β-arrestin-dependent signaling to erK. 10, 11 on the other hand, certain ligands of the µ-opioid receptor, including morphine and herkinorin, do not induce β-arrestin recruitment and receptor internalization while potently stimulating g-protein coupling. [12] [13] [14] We add here another piece of evidence for the concept that g-protein activation and β-arrestin coupling are 2 separate activities of 7tms, as we show the β-arrestin-mediated internalization of a nonsignaling decoy receptor, c5l2. c5l2 (or gpr77) is a high-affinity receptor for the complement fragment c5a and c5a-desarg, a naturally occurring cleavage product of c5a that lacks the c-terminal arginine (for review articles on c5l2, see monk et al. 15 and lee et al. 16 ). c5a is a potent chemoattractant for neutrophils and other immune cells and plays an important role in the innate immune response. the classical receptor for c5a (c5ar, cD88) is a g-protein-coupled receptor (gpcr) that primarily couples to gαi2, a pertussis toxin (ptX)-sensitive g-protein. 17 c5l2 shares 35% amino acid identity with c5ar. studies with inhibitory antibodies against rat c5l2 18 and studies with knockout mice strain deficient for c5l2 19, 20 suggest a critical role of this receptor in the innate immune response. studies by different groups investigating this receptor have found that c5l2 does not significantly activate g-protein or mapK signaling pathways. 21, 22 the lack of g-protein coupling has been related to the absence of a typical Dry motif (asp-arg-tyr) within the sequence of c5l2, which contains a arg to leu substitution (Dly). 22 conflicting data have been reported with regard to c5l2 internalization and the responsiveness of c5l2 to c3a. two groups could not detect internalization, 21, 22 whereas another group showed translocation of green fluorescent protein (gfp)-labeled β-arrestin in human embryonic kidney 293 (heK293) cells expressing c5l2. 23 redistribution of β-arrestin-gfp was shown upon stimulation with c5a, c5a-desarg, and c3a. 23 however, these effects were measured at a high (1 µm) ligand concentration 23 (i.e., approximately 1000 times higher than the affinity of c5l2 for c5a or c5a-desarg). 21, 22, 24 furthermore, the observation in this study 23 that c3a can activate c5l2 does not reconcile with the in vitro data reported by others. 21, 22, 24 to enable the identification of small-molecule drugs for human c5l2, we searched for an appropriate functional readout for this receptor. We found that c5a and c5a-desarg stimulated the redistribution of gfp-β-arrestin to cytoplasmic vesicles in human osteosarcoma (u2os) cells stably transfected with human c5l2 cDna. We confirmed direct interaction of ligand-activated c5l2 with β-arrestin by using a novel β-galactosidase fragment complementation assay in chinese hamster ovary (cho) cells. in this assay, human c5l2 was labeled with a mutationally altered peptide of β-galactosidase, 25 whereas β-arrestin was labeled with a corresponding ω deletion mutant of β-galactosidase. the activity of c5l2 on β-arrestin recruitment and redistribution was compared with that of the classical g-protein-coupled c5ar.
MATERIALS AND METHODS

Materials
human complement fragment c5a was purchased from sigma-aldrich (st. louis, mo). human c5a-desarg, c3a, and c3a-desarg were purchased from calbiochem (san Diego, ca). the c5ar inhibitor pmX-53 26 was purchased from neomps (san Diego, ca), and forskolin and ptX were from sigma-aldrich.
Cell lines
u2os cells were purchased from the american type culture collection (manassas, va). a cho cell line expressing a fusion protein of β-arrestin and a ω mutant of β-galactosidase was purchased from Discoverx (fremont, ca; product number 93-0164).
G-protein signaling
camp signaling was measured with the alphascreen assay (perkinelmer, boston, ma; product number 6760625r). to measure gαi coupling, we triggered intracellular camp levels by treatment of cells with 1 µm forskolin. calcium mobilization was measured with hithunter calcium no-wash assay kit from Discoverx (product number 90-0080l).
-arrestin redistribution
a β-arrestin-gfp fusion gene consisting of human β-arrestin2 and a mutationally altered, so-called enhanced gfp (egfp) of Aequoria victoria was constructed as follows: the Kozak sequence of the egfp gene of pegfp-n1 (clontech/bD bioscience, mountain view, ca; product number 6081-1) was removed. human β-arrestin2 cDna was isolated from heK293 cells by reverse-transcriptase pcr and cloned into the adapted pegfp-n1 vector. the resulting plasmid was transfected into u2os cells using fugene 6 (roche, basel, switzerland) according to the manufacturer's protocol. stable u2os β-arrestin2egfp cell lines were derived by antibiotic selection and single-cell subcloning by limited dilution. human c5l2 and c5ar cDna in pirespuro2 (clontech) were stably transfected into u2os β-arrestin2-egfp cells using fugene. clones stably expressing both β-arrestin2-egfp and the receptor were maintained in Dulbecco's modified eagle's medium: nutrient mixture f-12 (Dmem/f12) (invitrogen, carlsbad, ca), supplemented with 10% (vol/vol) fortified calf serum (fcs) (hyclone, logan, ut), 100 u/ml penicillin g, 100 µg/ml streptomycin, 800 µg/ml geneticin (invitrogen), and 2 µg/ml puromycin (calbiochem). for redistribution experiments, cells were seeded at 10,000 cells per well in a black 96-well clearbottom plate (perkinelmer) in 80 µl Dmem/f12 containing 2% (vol/vol) fcs and incubated overnight in a humidified atmosphere at 5% co 2 and 37 °c. the next day, 10 µl of Dmem/f12 containing 2% (vol/vol) fcs and 10 µg/ml hoechst 33342 (invitrogen) for nuclear staining were added for agonistic assays with the complement fragments (i.e., c5a, c5a-desarg, c3a, c3a-desarg). for antagonistic assays, 10 µl of various concentrations of pmX-53 in Dmem/f12 containing 2% (vol/vol) fcs and 10 µg/ml hoechst 33342 were added. after a 30-min incubation at 37 °c, 10 µl of complement fragments in Dmem/f12 containing 2% (vol/vol) fcs was added. after stimulation for 45 min at 37 °c, the cells were fixed with 2% (vol/vol) paraformaldehyde (usb, cleveland, oh) for 1 h at room temperature. subsequently, cells were washed 3 times with phosphate-buffered saline and analyzed with a Discovery-1 automated microscope (molecular Devices, sunnyvale, ca) using the ×20 objective. the translocation of β-arrestin2-egfp into vesicles was quantified using the metaXpress  gpcr cycling algorithm (molecular Devices). nuclei and vesicles were identified based on size and fluorescent intensity, and the average number of vesicles per cell was calculated. curves were fit by nonlinear regression using the sigmoidal dose-response equation in graphpad prism version 4.03 (graphpad, san Diego, ca).
Enzyme fragment complementation
human c5l2 or c5ar cDna was cloned into the nhei and hindiii site of the prolink cloning vector (Discoverx, product number 93-0167) and stably transfected into the β-arrestin cho cell line (Discoverx) using fugene 6. stable cell lines were maintained in Dmem/f12 supplemented with 10% (vol/ vol) fcs, 100 u/ml penicillin g, 100 µg/ml streptomycin, 800 µg/ml geneticin, and 250 µg/ml hygromycin. for β-galactosidase complementation assays, cells were seeded at a density of 10,000 cells per well in 384-well culture plates (perkinelmer) in 15 µl Dmem/f12 containing 1% (vol/vol) fetal bovine serum (fbs) (hyclone) and incubated overnight in a humidified atmosphere at 5% co 2 and 37 °c. the next day, 5 µl of Dmem/f12 containing 1% (vol/vol) fbs was added for agonistic assays with complement fragments. for antagonistic assays, 5 µl of various concentrations of pmX-53, diluted in Dmem/f12 containing 1% (vol/vol) fbs, was added. after a 30-min incubation at 37 °c, 5 µl of various concentrations of complement fragments in Dmem/f12 containing 1% (vol/vol) fbs was added. after incubation for 1 h at 37 °c and 1 h at room temperature, 12 µl per well of pathhunter detection reagent (Discoverx) was added, and the reaction was developed for 2 h at room temperature in the dark. chemiluminescence was measured on an envision multilabel reader (perkinelmer). pERK1/2 assays levels of phosphorylated erK1 and erK2 (perK) and total erK levels were determined by immunoblotting and using an erK1/2 fast activated cell-based elisa (face) kit from active motif  (carlsbad, ca). for immunoblotting, cells were seeded at a density of 150,000 cells/well in 24-well culture plates in culture medium and incubated overnight in a humidified atmosphere at 5% co 2 and 37 °c. subsequently, the cells were serum starved overnight in assay medium (Dmem/f12 supplemented with 100 u/ml penicillin g, 100 µg/ml streptomycin, 1 µg/ml insulin [Diosynth, oss, the netherlands], and 5 µg/ml apo-transferrin [sigma-aldrich]). Where indicated, cells were treated with 100 ng/ml ptX. the next day, the cells were stimulated with 100 nm c5a or vehicle (assay medium containing 0.1% bovine serum albumin [bsa]). after stimulation, media were removed and 150 µl of 2× laemmli sample buffer was added. Whole-cell lysates were resolved on a 4% to 12% bis-tris polyacrylamide gel (invitrogen) and transferred to nitrocellulose for immunoblotting. phosphorylated erK1/2 and total erK1/2 were detected with rabbit polyclonal anti-phospho-p44/42 mapK (cell signaling, beverly, ma) diluted 1:2000 and rabbit polyclonal anti-erK1/2 (biosource, camarillo, ca) diluted 1:2,000, respectively. chemiluminescent detection was performed using supersignal West Dura extended Duration substrate (thermo fisher scientific, Waltham, ma).
for the face assays, cells were seeded at a density of 15,000 cells/well in 96-well plates that had been coated with 0.1% gelatin and were incubated overnight in a humidified atmosphere at 5% co 2 and 37 °c. culture medium was replaced by 90 µl assay medium, containing, where indicated, 100 ng/ml ptX. the next day, the cells were stimulated for 5 min with different concentrations of c5a in 10 µl assay medium. cells were fixed by replacing the assay medium with 100 µl of 4% formaldehyde (bio-connect, huissen, the netherlands) in phosphate-buffered saline (pbs). after 20 min of incubation at room temperature, cells were washed 3 times with 200 µl wash buffer (0.1% [vol/vol] triton X-100 in pbs from the face kit) followed by an incubation of 20 min with 100 µl quenching buffer, containing 1% (vol/vol) hydrogen peroxide (thermo fisher scientific) and 0.1% (vol/vol) sodium azide (sigma-aldrich) in pbs. cells were washed 2 times with wash buffer, incubated for 1 h with 100 µl antibody blocking buffer from the kit, and washed 2 times again. then, 40 µl of diluted antibody against phosphorylated erK1/2 (1:500 from the face kit) was added and incubated overnight at 4 °c. the phospho-erK antibody has been raised against a synthetic phosphopeptide corresponding to residues thr202 and tyr204 of human erK1 and thr185 and tyr187 of human erK2. for the detection of total erK, antibody against erK1 and erK2 (1:500 from the face kit) was added. the excessive primary antibody was washed out, and 100 µl diluted hrp-conjugated antirabbit igg (1:2000 from the face kit) was added and incubated for 1 h at room temperature. secondary antibody was removed, and cells were washed 3 times with wash buffer and twice with pbs. then, 100 µl per well of face chemiluminescent working solution was added. chemiluminescence was measured on an envision multilabel reader.
RESULTS
consistent with previous reports from other groups, 21, 22 we did not detect any effect of c5l2 on gαi-, gαs-, and gαqprotein signaling pathways in gene transfection experiments and second-messenger assays in heK293 cells (data not shown). in contrast, c5ar decreased forskolin-induced intracellular camp levels in a ptX-sensitive manner, confirming signal transduction of c5ar via gαi-protein. 17 β-arrestin redistribution has been established as a broadly applicable assay platform to measure ligand activation of 7tms. 27, 28 We determined the effect of c5a on the redistribution of gfp-labeled β-arrestin2 ( Fig. 1A) in u2os cells stably expressing human c5l2. in nonstimulated cells, β-arrestin2gfp showed a diffuse cytoplasmic distribution (Fig. 2) . stimulation with c5a resulted in a dose-dependent redistribution of fluorescence to cytoplasmic vesicles. the effect was quantified using an algorithm that counts the number of fluorescent vesicles per cell, yielding an ec 50 of 2 nm (Fig. 3A,  Table 1 ). c5a-desarg also induced β-arrestin redistribution, whereas c3a and c3a-desarg were not active in the β-arrestin translocation assay. this is consistent with the reported lack of binding of c3a and c3a-desarg to c5l2, as previously reported by others. 21, 22, 24 in parallel, experiments were carried out with u2os β-arrestin-gfp cells stably expressing human c5ar. a similar distribution pattern was found as for c5l2, indicating relocalization of ligand-activated receptor to intracellular vesicles (Fig. 2) . c5a was approximately 4 times less potent on c5ar as compared to c5l2, whereas c5a-desarg was 72 times less potent ( Fig. 3, Table 1 ). this is in agreement with the higher affinity of c5a-desarg for c5l2 as compared to c5ar in radiolabeled ligand-binding experiments. 22 the efficacies of ligand activation of the 2 receptors-that is, the maximum number of vesicles per cell (y-axis in Fig. 3 )-were similar for c5a, but c5a-desarg was less efficacious on c5ar than c5a.
to determine whether the effect of c5l2 and c5ar on β-arrestin redistribution could be modulated with a small molecule, c5l2-and c5ar-expressing cells were treated with the Table 1 . potencies (pec 50 ± sD) of c5a and c5a-desarg on c5l2 and c5ar in β-arrestin2-gfp redistribution assay in stably transfected u2os cells and in β-arrestin β-galactosidase fragment complementation and alphascreen camp assays in stably transfected cho cells C5L2 C5aR β-Arrestin-GFP β-Galactosidase cAMP β-Arrestin2-GFP β-Galactosidase cAMP c5a 8.77 ± 0.19 (n = 3) 9.28 ± 0.08 (n = 3) inactive (n = 3) 8.14 ± 0.28 (n = 5) 8.23 ± 0.11 (n = 2) 8.96 ± 0.23 (n = 2) c5a-desarg 9.24 ± 0.34 (n = 2) 9.88 ± 0.13 (n = 3) inactive (n = 2) 7.38 ± 0.05 (n = 2) 7.49 ± 0.00 (n = 2) 8.96 ± 0.16 (n = 2) c3a inactive (n = 1) inactive (n = 2) inactive (n = 2) inactive (n = 1) inactive (n = 2) inactive (n = 2) c3a-desarg inactive (n = 1) inactive (n = 2) inactive (n = 2) inactive (n = 1) inactive (n = 2) inactive (n = 2) cho, chinese hamster ovary; gfp, green fluorescent protein. cyclic peptide c5ar antagonists pmX-53 26 and then stimulated with c5a at ec 80 concentration. pmX-53 inhibited ligandinduced β-arrestin redistribution through c5ar (pec 50 , 7.70 ± 0.066, n = 2) but not through c5l2 (Fig. 3) . these data confirm that pmX-53 is a specific inhibitor of c5ar. to investigate the interaction of c5l2 with β-arrestin in a different cellular context and experimental setting, we applied a novel chemiluminescence assay based on enzyme fragment complementation of β-galactosidase. 25, 29, 30 the principle of the assay is schematically drawn in Figure 1B . c5l2 was labeled at the c-terminus with a mutationally altered peptide fragment of β-galactosidase, 25 whereas β-arrestin2 was labeled with a corresponding ω deletion mutant of the enzyme. both the modified receptor and the fusion of β-arrestin and the β-galactosidase deletion mutant were stably expressed in cho cells. stimulation of the modified c5l2 receptor with c5a or c5a-desarg resulted in recruitment of the β-arrestin fusion protein and active β-galactosidase, as shown by an increase of chemiluminescent signal (Fig. 4A) . c3a and c3a-desarg did not induce β-galactosidase enzyme activity (Fig. 4A) . the potencies of c5a and c5a-desarg were in the same (sub)nanomolar range as those determined with the β-arrestin-gfp redistribution assay ( Table 1) . this indicates that the c-terminal modification of c5l2 with the β-galactosidase-derived peptide had not altered the ligand-binding properties of the receptor. the average Z′ factor of the assay was 0.72, which means a good assay quality.
We also developed a β-arrestin recruitment assay for c5ar based on the β-galactosidase fragment complementation technology. both c5a and c5a-desarg induced enzyme fragment complementation, whereas c3a and c3-desarg were inactive (Fig. 4B) . the efficacy of c5a-desarg was lower than that of c5a (y-axis in Fig. 4B) , like in the β-arrestin translocation assay (Fig. 3B) . stimulation of β-arrestin recruitment with c5a could be inhibited with pmX-53 ( Fig. 4B; pec 50 , 7.18 ± 0.015, n = 2). the average Z′ factor of the assay was 0.95, which means an excellent assay quality. to determine whether the modified c5ar could still couple to gαi-protein, we performed camp assays in the cho cell line. both c5a and c5a-desarg inhibited forskolin-induced camp accumulation mediated by c5ar ( Fig. 5) . the potency (ec 50 ) for c5a was 5 times lower than in the β-arrestin recruitment assay ( Table 1 ), suggesting that higher agonist concentrations are needed to trigger desensitization, whereas lower concentrations mediate cellular responses to gpcr functions. remarkably, c5a-desarg was equally potent to c5a in the camp assay ( Fig. 5) . this is remarkable because in the β-arrestin recruitment assays employed in the same cell line ( Figs. 3-4) , c5a-desarg behaved as a partial agonist and was approximately 6 times less potent than c5a ( Table 1) . no inhibition of forskolin-induced camp accumulation was detected when the cho cell line expressing the modified c5l2 was stimulated with c5a or c5a-desarg ( Table 1) .
because β-arrestin can couple 7tms to the mapK signaling pathway, 8 we examined whether β-arrestin recruitment coincided with the induction of erK1/2 phosphorylation in the cho cell lines that had been used for the enzyme fragment complementation assay. erK1/2 phosphorylation was determined by immunoblotting ( Fig. 6) and using a cell-based enzyme-linked immunosorbent assay (elisa; Fig. 7) , allowing the quantitative determination of potencies of activation. to determine the role of gαi-protein in the activation of erK1/2, experiments were carried out with ptX. ptX catalyzes the adenosine diphosphate (aDp) ribosylation of gαi-and gαoproteins, preventing their binding to activated receptors. 31 as can be seen in Figure 6 , incubation of the cell lines with vehicle resulted in a small increase of erK1/2 phosphorylation in the first 10 min due to a trophic response. this response was gα i -protein mediated, as it was sensitive to ptX. in the cell line expressing the modified c5l2 and in the parental cell line, stimulation with c5a resulted in a small further increase in erK1/2 phosphorylation (Fig. 6) . because the increase in the c5l2-expressing cell line was quantitatively the same as in the parental cell line, we conclude that the c5a-stimulated activation of erK1/2 is mediated through an endogenous c5a receptor in cho cells. in contrast, c5a strongly activated erK1/2 phosphorylation in the cell line expressing the modified c5ar ( Fig. 6) , with a pec 50 of 10.34 ± 0.15 (n = 3; Fig. 7) . as can be seen in Figures 6 and 7 , ptX completely blocked c5astimulated erK1/2 phosphorylation, indicating that the activation of erK1/2 by ligand stimulation of c5ar was g-protein dependent and not mediated by β-arrestin.
DISCUSSION
We show here that the non-g-protein-signaling c5l2 receptor recruits β-arrestin2 in a ligand-dependent manner. the potencies of c5a and c5a-desarg in the β-arrestin assays were in the same nanomolar range as their affinities in binding experiments, 21, 22, 24 suggesting that the effect of ligand-activated c5l2 on β-arrestin may occur in vivo under physiological conditions. this remains to be confirmed, however. the agonistic activities of c5a on c5l2-β-arrestin2 redistribution/ recruitment were not inhibited by the c5a receptor antagonist pmX-53, suggesting that c5l2 probably not only is a decoy receptor but also can mediate cellular functions different from those associated to its c5ar homolog.
two different methodologies to study β-arrestin-7tm interaction were used: a high-content imaging assay with fluorescently labeled β-arrestin and a novel β-galactosidase fragment complementation assay. Due to its simple format, the latter is highly suitable for automated screening for modulators of 7tms, as we have recently shown for another signaling 7tm, eDg1. 30 another advantage of this technique is that it uses a tagged receptor, excluding signal interference from endogenous receptors. furthermore, as we have shown for c5ar (this article) and eDg1, 30 the receptor tag does not interfere with g-protein coupling. β-arrestin assays are becoming an increasingly popular tool for drug discovery on gpcrs. 28 With our study, we show that the application of β-arrestin can be extended to nonsignaling 7tms. the potency of c5a stimulation of c5l2 in the β-arrestin assay was slightly lower than that of the classical g-proteincoupled c5ar. in the β-galactosidase fragment complementation assay, a 10-fold lower ec 50 was measured. for c5a-desarg, an approximately 100-fold lower potency on c5l2 was measured with both assay methods, consistent with the preference of c5a-desarg for binding to c5l2. 21, 22, 24 originally, β-arrestin recruitment was thought to follow and strictly depend on g-protein activation of 7tms. the discovery of dissociating ligands and studies with receptor mutants and β-arrestin knockouts have challenged this classical view. 9 in addition, frizzled 4 and smoothened have been shown to bind to β-arrestin, but both 7tms do not seem to couple to g-proteins. 32, 33 the observation that the non-g-protein signaling c5l2 recruits β-arrestin in a ligand-dependent manner further supports the idea that g-protein coupling and β-arrestin can be 2 separate activities of 7tms.
β-arrestin coupling has been linked to activation of erK1/2 phosphorylation for several receptors in several systems. 8 ligand stimulation of c5ar resulted in activation of erK1/2 FIG. 5. Dose-response curves for c5ar-mediated inhibition of forskolin-induced camp accumulation. graphs shown are from chinese hamster ovary (cho) cells expressing c5ar that were incubated with c5a (□) or c5a-desarg (■) at ec 80 concentration forskolin. the concentration of camp in the cells was measured using the alphascreen camp assay. phosphorylation in the cho cell line used for the β-galactosidase fragment complementation assay ( Figs. 6-7) . however, this activation was gαi-protein dependent, as it could be blocked with ptX and was not mediated by β-arrestin. We found that stimulation of c5l2 does not result in activation of erK1/2 phosphorylation ( Figs. 6-7) .
based on the redistribution pattern in assays with β-arrestingfp, 7tms have been divided into 2 distinct classes. 27, 34 agonist activation of class a receptors results in the formation of distinct punctae (so-called pits) at the plasma membrane. agonist activation of class b receptors results in relocalization of β-arrestin-gfp to endocytic vesicles. the distribution pattern in our high-content imaging experiments (Fig. 2) suggests that c5l2 is a class b receptor, as was demonstrated previously for c5ar. 35 the interaction of c5l2 may be specific for β-arrestin2, as in a recent article, scola et al. 36 reported that c5l2 is unable to induce translocation of β-arrestin1.
c5l2 is thought to function as a scavenger or decoy receptor involved in the regulation of circulating complement factors. 22, 36 other chemoattractant receptors with decoy function are the chemokine receptors Duffy antigen/receptor for chemokines (Darc), D6, and ccX-cKr. 37 although c5l2 shows high selectivity for its ligands c5a and c5a-desarg, these other receptors are more promiscuous and bind to several different chemokines. D6 was reported to internalize via a β-arrestin pathway. 38 however, unlike c5l2, D6 binds constitutively to β-arrestin, and internalization is ligand independent. 38 Darc was recently shown to oligomerize with ccr5 and to functionally antagonize its activity when coexpressed in the same cell line. 39 heterodimerization has also been proposed as a mechanism to explain the modulating activity of c5l2 on c5ar function. 19 however, chen et al. 20 reported that they were unable to detect interactions between c5l2 and c5ar. other mechanisms of cross-talk therefore need to be considered. We can speculate that if β-arrestin amounts would be critical in certain cell types or under certain physiological or experimental conditions, then the sequestration of β-arrestin by ligand-bound c5l2 would influence the internalization and recycling of other ligand-activated 7tms, such as c5ar. there is extensive evidence based on studies with knockout mice that β-arrestin2 has a modulatory function in the inflammatory response. 40, 41 further work is needed to elucidate the enigmatic role of c5l2 in the regulation of complement-activated inflammatory response. our data add one piece to the puzzle and provide β-arrestin as a functional read-out for high-throughput screening for drug discovery on this receptor.
